Tourette syndrome, associated conditions and the complexities of treatment

Brain

Volumn 123, Issue 3, 2000, Pages 425-462

  Robertson, Mary M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Clinical phenomenology; Psychopathology; Tourette syndrome; Treatment

Indexed keywords

ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIVIRUS AGENT; BOTULINUM TOXIN; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; CANNABIS; CENTRAL STIMULANT AGENT; CLONAZEPAM; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; IMMUNOMODULATING AGENT; LITHIUM; LITHIUM ACETATE; LITHIUM CARBONATE; NEUROLEPTIC AGENT; NICOTINE; PIMOZIDE; PROADEL; UNCLASSIFIED DRUG;

AGGRESSION; AKATHISIA; AMENORRHEA; ANXIETY; ATTENTION DEFICIT DISORDER; BEHAVIOR; CLINICAL FEATURE; COGNITION; DEPRESSION; DISEASE ASSOCIATION; DROWSINESS; DYSPHORIA; DYSTONIA; FATIGUE; GALACTORRHEA; GENETICS; GILLES DE LA TOURETTE SYNDROME; GYNECOMASTIA; HEART ARRHYTHMIA; HORMONAL THERAPY; HUMAN; LASER SURGERY; MENTAL DISEASE; NEUROLEPTIC MALIGNANT SYNDROME; OBSESSION; PARKINSONISM; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; TARDIVE DYSKINESIA; TIC; VERTIGO;

EID: 0033983916     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/123.3.425     Document Type: Review

References (468)

1. Abwender DA, Como PG, Kurlan R, Parry K, Fett KA, Cui L, et al. School problems in Tourette's syndrome. Arch Neurol 1996; 53: 509-11.
2. Adler LA, Angrist B, Peselow E, Reitano J, Rotrosen J. Clonidine in neuroleptic-induced akathisia. Am J Psychiatry 1987; 144: 235-6.
3. Ahmed I, Dagincourt PG, Miller LG, Shader RI. Possible interaction between fluoxetine and pimozide causing sinus bradycardia. Can J Psychiatry 1993; 38: 62-3.
4. Alessi NE, Walden ME, Hsieh PS. Nifedipine augments haloperidol in the treatment of Tourette syndrome. Pediatr Neurol 1988; 4: 191.
5. Alessi NE, Walden M, Hsieh PS. Nifedipine-haloperidol combination in the treatment of Gilles de la Tourette's syndrome: a case study. J Clin Psychiatry 1989; 50: 103-4.
6. Allen AJ, Leonard HL, Swedo SE. Case study: a new infection-triggered, autoimmune subtype of pediatric OCD and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1995; 34: 307-11.
7. Alsobrook JP 2nd, Pauls DL. The genetics of Tourette syndrome. [Review]. Neurol Clin 1997; 15: 381-93.
8. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington (DC): American Psychiatric Association; 1980.
9. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. DSM-III-R. 3rd ed., rev. Washington (DC): American Psychiatric Association; 1987.
10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. DSM-IV. 4th ed. Washington (DC): American Psychiatric Association; 1994.
11. Ananth J. Impotence associated with pimozide [letter]. Am J Psychiatry 1982; 139: 1374.
12. Apter A, Pauls DL, Bleich A, Zohar AH, Kron S, Ratzoni G, et al. A population-based epidemiological study of Tourette syndrome among adolescents in Israel. Adv Neurol 1992; 58: 61-5.
13. Apter A, Pauls DL, Bleich A, Zohar AH, Kron S, Ratzoni G, et al. An epidemiologic study of Gilles de la Tourette's syndrome in Israel. Arch Gen Psychiatry 1993; 50: 734-8.
14. Arevalo E, Licamele WL, Bronheim S, Sonnenschein K. Nicotine gum in Tourette's disorder [letter]. Am J Psychiatry 1992; 149: 417-8.
15. Awaad Y, Michon AM. Tics/Tourette syndrome and new treatment options [abstract]. Mov Disord 1996; 11 Suppl 1: 248.
16. Baker GB, Chokka PR, Bornstein RA. Neurochemical and some related psychopharmacological aspects of Tourette's syndrome: an update. J Psychopharmacol 1995; 9: 273-80.
17. Banerjee S, Mason A, Eapen V, Zeitlin H, Robertson M. Prevalence of Tourette syndrome in a mainstream school population. Developmental Medicine and Child Neurology 1998; 40: 817-8.
18. Barabas G, Matthews WS. Coincident infantile autism and Tourette syndrome: a case report. J Dev Behav Pediatr 1983; 4: 280-1.
19. Barnes TRE, McPhillips MA. Antipsychotic-induced extrapyramidal symptoms. CNS Drugs 1996; 6: 315-30.
20. Barnes TR, Halstead SM, Little PW. Relationship between iron status and chronic akathisia in an in-patient population with chronic schizophrenia. Br J Psychiatry 1992; 161: 791-6.
21. Baron-Cohen S, Mortimore C, Moriarty J, Izaguirre J, Robertson M. The prevalence of Gilles de la Tourette's syndrome in children and adolescents with autism. J Child Psychol Psychiatry 1999a; 40: 213-8.
22. Baron-Cohen S, Scahill VL, Izaguirre J, Hornsey H, Robertson MM. The prevalence of Gilles de la Tourette syndrome in children and adolescents with autism: a large scale study. Psychol Med 1999b; 29: 1151-9.
23. Bazire S. Psychotropic drug directory. The professionals' pocket handbook and aide memoire. Snow Hill (UK): Mark Allen Publishing; 1997.
24. Benowitz NL. Pharmacology of nicotine: addiction and therapeutics. [Review]. Annu Rev Pharmacol Toxicol 1996; 36: 597-613.
25. Berg R. A case of Tourette syndrome treated with nifedipine. Acta Psychiatr Scand 1985; 72: 400-1.
26. Bergin A, Waranch HR, Brown J, Carson K, Singer HS. Relaxation therapy in Tourette syndrome: a pilot study. Pediatr Neurol 1998; 18: 136-42.
27. Berkson J. Limitations of the application of fourfold table analysis to hospital data. Biometrics 1946; 2: 47-51.
28. Berthier ML, Kulisevsky J, Campos VM. Bipolar disorder in adult patients with Tourette's syndrome: a clinical study. Biol Psychiatry 1998; 43: 364-70.
29. Bhadrinath BR. Olanzapine in Tourette syndrome [letter]. Br J Psychiatry 1998; 172: 366.
30. Biederman J, Gastfriend DR, Jellinek MS. Desipramine in the treatment of children with attention deficit disorder. J Clin Psychopharmacol 1986; 6: 359-63.
31. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry 1989a; 28: 777-84.
32. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS, Goldblatt A. A double-blind placebo controlled study of desipramine in the treatment of ADD: II. Serum drug levels and cardiovascular findings. J Am Acad Child Adolesc Psychiatry 1989b; 28: 903-11.
33. Billings A. Self-monitoring in the treatment of tics: a single-subject analysis. J Behav Ther Exp Psychiatry 1978; 9: 339-42.
34. Bondarenko ES, Iur'eva EA, Zykov VP, Alekseeva NV. [The laser therapy of children with Tourette's syndrome]. [Russian]. Zh Nevropatol Psikhiatr Im S S Korsakova 1997; 97: 29-32.
35. Borcherding BG, Keysor CS, Rapoport JL, Elia J, Amass J. Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability? Psychiatry Res 1990; 33: 83-94.
36. Boris M. Gilles de la Tourette's syndrome: remission with haloperidol [letter]. JAMA 1968; 205: 648-9.
37. Borison RL, Ang L, Hamilton WJ, Diamond BI, Davis JM. Treatment approaches in Gilles de la Tourette syndrome. Brain Res Bull 1983; 11: 205-8.
38. Bornstein RA, Stefl ME, Hammond L. A survey of Tourette syndrome patients and their families: the 1987 Ohio Tourette Survey. J Neuropsychiatry Clin Neurosci 1990; 2: 275-81.
39. Bouchard RH, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effects [letter]. Am J Psychiatry 1989; 146: 1352-3.
40. Braun A, Mouradian MM, Mohr E, Fabbrini G, Chase TN. Selective D-1 dopamine receptor agonist effects in hyperkinetic extra-pyramidal disorders. J Neurol Neurosurg Psychiatry 1989; 52: 631-5.
41. Brill CB. Gum chewing as therapy for Tourette syndrome. Pediatr Neurol 1988; 4: 128.
42. British National Formulary. BNF 35, March 1998. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 1998.
43. Browne TR. Clonazepam. N Engl J Med 1978; 299: 812-6.
44. Bruggeman R, van der Linden C, van Woerkom CAM. Risperidone in the treatment of Gilles de la Tourette's syndrome - an open dose finding study. Neuropsychopharmacology 1994; 10: (3S Suppl Pt 2); 42S: O-115-163.
45. Bruun RD. Dysphoric phenomena associated with haloperidol treatment of Tourette syndrome. Adv Neurol 1982; 35: 433-6.
46. Bruun RD. Gilles de la Tourette's syndrome: an overview of clinical experience. J Am Acad Child Psychiatry 1984; 23: 126-33.
47. Bruun RD. Subtle and underrecognized side effects of neuroleptic treatment in children with Tourette's disorder. Am J Psychiatry 1988; 145: 621-4.
48. Bruun RD, Budman CL. Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry 1996; 57: 29-31.
49. Bruun RD, Budman CL. The course and prognosis of Tourette syndrome. [Review]. Neurol Clin 1997; 15: 291-8.
50. Bruun RD, Shapiro AK, Shapiro E, Sweet R, Wayne H, Solomon GE. A follow-up of 78 patients with Gilles de la Tourette's syndrome. Am J Psychiatry 1976; 133: 944-7.
51. Budman CL, Sherling M, Bruun RD. Combined pharmacotherapy risk [letter]. J Am Acad Child Adolesc Psychiatry 1995; 34: 263-4.
52. Budman CL, Kerjakovic M, Bruun RD. Viral infection and tic exacerbation [letter]. J Am Acad Child Adolesc Psychiatry 1997; 36: 162.
53. Buitelaar JK, Cohen-Kettenis P, Vlutters H, Westenberg H, Sandell L. Remoxipride in adolescents with Tourette's syndrome: an open pilot study. J Child Adolesc Psychopharmacol 1995; 5: 121-8.
54. Buitelaar JK, De Bruin WI, van Rijk PP. SPECT studies in Tourette's syndrome. In: Garreau B, editor. Neuroimaging in child neuropsychiatric disorders. Berlin: Springer-Verlag; 1998. p. 133-9.
55. Caine ED, Polinsky RJ. Haloperidol-induced dysphoria in patients with Tourette syndrome. Am J Psychiatry 1979; 136: 1216-7.
56. Caine ED, Polinsky RJ. Tardive dyskinesia in persons with Gilles de la Tourette's disease [letter]. Arch Neurol 1981; 38: 471-2.
57. Caine ED, Margolin DI, Brown GL, Ebert MH. Gilles de la Tourette's syndrome, tardive dyskinesia, and psychosis in an adolescent. Am J Psychiatry 1978; 135: 241-3.
58. Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979; 136: 317-20.
59. Caine ED, McBride MC, Chiverton P, Bamford KA, Rediess S, Shiao J. Tourette's syndrome in Monroe County school children. Neurology 1988; 38: 472-5.
60. Caprini G, Melotti V. Un grave sindrome ticcosa guarita con haloperidol. Riv Sper Freniatr Med Leg Alienazioni Ment 1961; 85: 191-6.
61. Carrey NJ, Wiggins DM, Milin RP. Pharmacological treatment of psychiatric disorders in children and adolescents: focus on guidelines for the primary care practitioner. [Review]. Drugs 1996; 51: 750-9.
62. Castellanos FX, Giedd JN, Elia J, Marsh WL, Ritchie GF, Hamburger SD, et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 1997; 36: 589-96.
63. Challas G, Brauer W. Tourette's disease: relief of symptoms with R1625. Am J Psychiatry 1963; 120: 283-4.
64. Chapel JL, Brown N, Jenkins RL. Tourette's disease: symptomatic relief with haloperidol. Am J Psychiatry 1964; 121: 608-10.
65. Chaplin S. Helping patients shake off tardive dyskinesia. Hosp Doct 1991; 20: 39.
66. Chappell P, Riddle M, Anderson G, Scahill L, Hardin M, Walker D, et al. Enhanced stress responsivity of Tourette syndrome patients undergoing lumbar puncture. Biol Psychiatry 1994; 36: 35-43.
67. Chappell PB, Leckman JF, Riddle MA. The pharmacologic treatment of tic disorders. Child Adolesc Psychiatr Clin North Am 1995a; 4: 197-216.
68. Chappell PB, Riddle MA, Scahill L, Lynch KA, Schultz R, Arnsten A, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995b; 34: 1140-6.
69. Chappell PB, Scahill LD, Leckman JF. Future therapies of Tourette syndrome. [Review]. Neurol Clin 1997; 15: 429-50.
70. Chee KY, Sachdev P. The clinical features of Tourette's disorder: an Australian study using a structured interview schedule. Aust NZJ Psychiatry 1994; 28: 313-8.
71. Cheng Y, Jiang DH. [Therapeutic effect of inosine in Tourette syndrome and its possible mechanism of action]. [Chinese]. Chung Hua Shen Ching Ching Shen Ko Tsa Chih 1990; 23: 90-3, 126-7.
72. Choo V. Paroxetine and exrapyramidal reactions. Lancet 1993; 341: 624.
73. Chouza C, Romero S, Lorenzo J, Camano JL, Fontana AP, Alterwain P, et al. [Clinical trial of tiapride in patients with dyskinesia (author's transl)]. [French] Sem Hop 1982; 58: 725-33.
74. Clarke DJ, Ford R. Treatment of refractory Tourette syndrome with haloperidol decanoate. Acta Psychiatr Scand 1988; 77: 495-6.
75. Coffey B, Frazier J, Chen S. Comorbidity, Tourette syndrome, and anxiety disorders. [Review]. Adv Neurol 1992; 58: 95-104.
76. Cohen AJ, Leckman JF. Sensory phenomena associated with Gilles de la Tourette's syndrome. J Clin Psychiatry 1992; 53: 319-23.
77. Cohen DJ, Detlor J, Young JG, Shaywitz BA. Clonidine ameliorates Gilles de la Tourette syndrome. Arch Gen Psychiatry 1980; 37: 1350-7.
78. Cohen DJ, Detlor J, Young JG, Shaywitz BA. Clonidine and haloperidol in Gilles de la Tourette syndrome [letter]. Arch Gen Psychiatry 1981; 38: 1184-5.
79. Cohn LM, Caliendo GC. Guanfacine use in children with attention deficit hyperactivity disorder [letter]. Ann Pharmacother 1997; 31: 918-9.
80. Comings D. Tourette syndrome and human behaviour. Duarte (CA): Hope Press; 1990.
81. Comings DE. DSM-IV criteria for Tourette's [letter]. J Am Acad Child Adolesc Psychiatry 1995; 34: 401-2.
82. Comings DE. Comings BG. Tourette's syndrome and attention deficit disorder with hyperactivity: are they genetically related? J Am Acad Child Psychiatry 1984; 23: 138-46.
83. Comings DE, Comings BG. A controlled study of Tourette syndrome. I-VII. Am J Hum Genet 1987; 41: 701-866.
84. Comings DE, Hines JA, Comings BG. An epidemiologic study of Tourette's syndrome in a single school district. J Clin Psychiatry 1990; 51: 563-9.
85. Comings DE, Wu S, Chiu C, Ring RH, Gade R, Ahn C, et al. Polygenic inheritance of Tourette syndrome, stuttering, attention deficit hyperactivity, conduct, and oppositional defiant disorder: the additive and subtractive effect of the three dopaminergic genes -DRD2, DβH, and DAT1. Am J Med Genet 1996; 67: 264-88.
86. Como PG. Tourette syndrome. Neuropsychological tests for obsessive-compulsive disorder and attention deficit hyperactivity disorder. [Review]. Neurol Clin 1997; 15: 255-65.
87. Como PG, Kurlan R. An open-label trial of fluoxetine for obsessive-compulsive disorder in Gilles de la Tourette's syndrome. Neurology 1991; 41: 872-4.
88. Connell PH, Corbett JA, Horne DJ, Mathews AM. Drug treatment of adolescent tiqueurs. A double-blind trial of diazepam and haloperidol. Br J Psychiatry 1967; 113: 375-81.
89. Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986; 30: 277-82.
90. Corbett JA, Matthews AM, Connell PH, Shapiro DA. Tics and Gilles de la Tourette's syndrome: a follow-up study and critical review. Br J Psychiatry 1969; 115: 1229-11.
91. Costello EJ, Angold A, Burns BJ, Stangl DK, Tweed DL, Erkanli A, et al. The Great Smoky Mountains Study of Youth, Goals, design, methods, and the prevalence of DSM-111-R disorders. Arch Gen Psychiatry 1996; 53: 1129-36.
92. Curtis D, Robertson MM, Gurling HM. Autosomal dominant gene transmission in a large kindred with Gilles de la Tourette syndrome. Br J Psychiatry 1992; 160: 845-9.
93. Davila DG, Hurt RD, Offord KP, Harris CD, Shepard JW Jr. Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in non-smokers. Am J Respir Crit Care Med 1994; 150: 469-74.
94. De Groot C, Bornstein R, Spetier L, Burriss B. The course of tics in Tourette syndrome: a 5 year follow up study. Ann Clin Psychiatry 1994; 6: 227-33.
95. De Veaugh-Geiss J. Tardive Tourette syndrome. Neurology 1980; 30: 562-3.
96. Delay J, Pichot P, Lemperiere T, Elissalde B, Peigne F. Neuroleptique majeur non phenothiazine et non reserpinique, l'haloperidol, dans le traitement des psychoses. Ann Med Psychol 1960; 118: 145-52.
97. Delgado PL, Goodman WK, Price LH, Heninger GR, Charney DS. Fluvoxamine/pimozide treatment of concurrent Tourette's and obsessive-compulsive disorder. Br J Psychiatry 1990; 157: 762-5.
98. Desai AB, Doongaji DR, Satoskar RS. Metoclopramide in Gilles de la Tourette's syndrome (a case report). J Postgrad Med 1983; 29: 181-3.
99. Devor EJ, Isenberg KE. Nicotine and Tourette's syndrome [letter]. Lancet 1989; 2: 1046.
100. Dillon JE. Self-injurious behavior associated with clonidine withdrawal in a child with Tourette's disorder. J Child Neurol 1990; 5: 308-10.
101. Dillon DC, Salzman IJ, Schulsinger DA. The use of imipramine in Tourette's syndrome and attention deficit disorder: case report. J Clin Psychiatry 1985; 46: 348-9.
102. Dinan TG. Obsessive compulsive disorder: the paradigm shift. J Serotonin Res 1995; 1 Suppl 1: 19-25.
103. Dion Y, Chouinard G. Treatment of Gilles de la Tourette syndrome with clonazepam. In: 10th Annual Meeting of Canadian College of Neuropsychopharmacology, CCNP; 1987 May 19-22; p.w-17. Rivotril G-6543.
104. Dion Y, Chouinard G. Treatment of Gilles de la Tourette syndrome with clonazepam. In: Canadian Psychiatric Association - 38th Annual Meeting, Halifax (NS). 1988 Sep 28-30; Abstracts Book 1988. p. 119. Rivotril H-10764 (Clonazepam).
105. Dowson JH. Assessment of DSM-III-R personality disorders by self-report questionnaire: the role of informants and a screening test for co-morbid personality disorders (STCPD). Br J Psychiatry 1992; 161: 344-52.
106. Drtilková I, Balaötiková B, Lemanová H, Zák J. Therapeutical effects of clonidine and clonazepam in children with tick syndrome. Homeost Health Dis 1994; 35: 296.
107. Dursun SM, Reveley MA. The efficacy of a dose-escalated application of transdermal nicotine plus sulpiride in Tourette's syndrome. Eur Psychiatry 1996; 11: 204-6.
108. Dursun SM, Reveley MA. Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette's syndrome: an open study. Psychol Med 1997; 27: 483-7.
109. Dursun SM, Reveley MA, Bird R, Stirton F. Longlasting improvement of Tourette's syndrome with transdermal nicotine [letter]. Lancet 1994; 344: 1577.
110. Dursun SM, Burke JG, Reveley MA. Buspirone treatment of Tourette's syndrome [letter]. Lancet 1995; 345: 1366-7.
111. Dysken MW, Berecz JM, Samarza A, Davis JM. Clonidine in Tourette syndrome [letter]. Lancet 1980; 2: 926-7.
112. Eapen V, Robertson MM. Gilles de la Tourette syndrome and attention deficit disorder - no evidence for a genetic relationship. J Neuropsychiatr Neuropsychol Behav Neurol 1996; 9: 192-6.
113. Eapen V, Pauls DL, Robertson MM. Evidence for autosomal dominant transmission in Tourette's syndrome. United Kingdom cohort study. Br J Psychiatry 1993a; 162: 593-6.
114. Eapen V, Katona CLE, Barnes TRE, Robertson MM. Sulpiride-induced tardive dyskinesia in a person with Gilles de la Tourette syndrome. J Psychopharmacol 1993b; 7: 290-2.
115. Eapen V, Trimble MR, Robertson MM. The use of fluoxetine in Gilles de la Tourette syndrome and obsessive compulsive behaviours: preliminary clinical experience. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 737-43.
116. Eapen V, Robertson MM, Zeitlin H, Kurlan R. Gilles de la Tourette's syndrome in special education schools: a United Kingdom study. J Neurol 1997a; 244: 378-82.
117. Eapen V, Robertson MM, Alsobrook JP 2nd, Pauls DL. Obsessive compulsive symptoms in Gilles de la Tourette syndrome and obsessive compulsive disorder: differences by diagnosis and family history. Am J Med Genet 1997b; 74: 432-8.
118. Eapen V, O'Neill J, Gurling HM, Robertson MM. Sex of parent transmission effect in Tourette's syndrome: evidence for earlier age at onset in maternally transmitted cases suggests a genomic imprinting effect. Neurology 1997c; 48: 934-7.
119. Edell BH, Motta RW. The emotional adjustment of children with Tourette's syndrome. J Psychol 1989; 123: 51-7.
120. Egan MF, Hyde TM, Albers GW, Elkashef A, Alexander RC, Reeve A, et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992; 149: 773-7.
121. Eggers C, Rothenberger A, Berghaus U. Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci 1988; 237: 223-9.
122. Eisenberg L, Ascher E, Kanner L. A clinical study of Gilles de la Tourette's disease (maladie des tics) in children. Am J Psychiatry 1959; 115: 715-23.
123. Emerich DF, Zanol MD, Norman AB, McConville BJ, Sanberg PR. Nicotine potentiates haloperidol-induced catalepsy and locomotor hypoactivity. Pharmacol Biochem Behav 1991; 38: 875-80.
124. Erenberg G, Fahn S. Tourette syndrome [letter]. Arch Neurol 1996; 53: 588.
125. Erenberg G, Cruse RP, Rothner AD. The natural history of Tourette syndrome: a follow-up study. Ann Neurol 1987; 22: 383-5.
126. Erickson HM Jr, Goggin JE, Messiha FS. Comparison of lithium and haloperidol therapy in Gilles de la Tourette syndrome. Adv Exp Med Biol 1977; 90: 197-205.
127. Evers RA, van de Wetering BJ. A treatment model for motor tics based on a specific tension-reduction technique. J Behav Ther Exp Psychiatry 1994; 25: 255-60.
128. Faux EJ. Gilles de la Tourette syndrome. Social psychiatric management. Arch Gen Psychiatry 1966; 14: 139-42.
129. Feigin A, Kurlan R, McDermott MP, Beach J, Dimitsopulos T, Brower CA, et al. A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder. Neurology 1996; 46: 965-8.
130. Feinberg M, Carroll BJ. Effects of dopamine agonists and antagonists in Tourette's disease. Arch Gen Psychiatry 1979; 36: 979-85.
131. Feldman J. Alternative drug treatments in Gilles de la Tourette's syndrome [letter]. Am J Psychiatry 1977; 134: 99.
132. Fennig S, Fennig SN, Pato M, Weitzman A. Emergence of symptoms of Tourette's syndrome during fluvoxamine treatment of obsessive-compulsive disorder. Br J Psychiatry 1994; 164: 839-41.
133. Fernando SJ. Gilles de la Tourette's syndrome. A report on four cases and a review of published case reports. [Review]. Br J Psychiatry 1967; 113: 607-17.
134. Ferrari M, Matthews WS, Barabas G. Children with Tourette syndrome: results of psychological tests given prior to drug treatment. J Dev Behav Pediatr 1984; 5: 116-9.
135. Finney JW, Christophersen ER, Ziegler DK. Deanol and Tourette syndrome [letter]. Lancet 1981; 2: 989.
136. Flament MF, Rapoport JL, Berg CJ, Sceery W, Kilts C, Mellstrom B, et al. Clomipramine treatment of childhood obsessive-compulsive disorder: a double-blind controlled study. Arch Gen Psychiatry 1985; 42: 977-83.
137. Fog R, Regeur L. Neuropharmacology of tics. Rev Neurol (Paris) 1986; 142: 856-9.
138. Frankel M, Cummings JL, Robertson MM, Trimble MR, Hill MA, Benson DF. Obsessions and compulsions in Gilles de la Tourette's syndrome. Neurology 1986; 36: 378-82.
139. Freeman RD. Attention deficit hyperactivity disorder in the presence of Tourette syndrome. [Review]. Neurol Clin 1997; 15: 411-20.
140. Freeman RD, Fast DK, Kent M. DSM-IV criteria for Tourette's [letter]. J Am Acad Child Adolesc Psychiatry 1995; 34: 400-1.
141. Fulop G, Phillips RA, Shapiro AK, Gomes JA, Shapiro E, Nordlie JW. ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 1987; 144: 673-5.
142. Fulton WA, Shady GA, Champion LM. An evaluation of Tourette syndrome and medication use in Canada. Neurosci Biobehav Rev 1988; 12: 251-4.
143. Gadow KD, Nolan EE, Sverd J. Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short-term behavioral effects in school settings. J Am Acad Child Adolesc Psychiatry 1992; 31: 462-71.
144. Gadow KD, Nolan E, Sprafkin J, Sverd J. School observations of children with attention-deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. J Dev Behav Pediatr 1995; 16: 167-76.
145. Gancher S, Conant-Norville D, Angell R. Treatment of Tourette's syndrome with transdermal clonidine: a pilot study. J Neuropsychiatry Clin Neurosci 1990; 2: 66-9.
146. Gardner AR, Gardner AJ. Self-mutilation, obsessionality and narcissism. Br J Psychiatry 1975; 127: 127-32.
147. George MS, Trimble MR, Ring HA, Sallee FR, Robertson MM. Obsessions in obsessive-compulsive disorder with and without Gilles de la Tourette's syndrome. Am J Psychiatry 1993a; 150: 93-7.
148. George MS, Trimble MR, Robertson MM. Fluvoxamine and sulpiride in comorbid obsessive-compulsive disorder and Gilles de la Tourette syndrome. Hum Psychopharmacol 1993b; 8: 327-34.
149. Gerlach J, Casey DE. Sulpiride in tardive dyskinesia. Acta Psychiatr Scand Suppl 1984; 311: 93-102.
150. Giakas WJ. Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder [letter]. Am J Psychiatry 1995; 152: 1097-8.
151. Gilles de la Tourette G. Etude sur une affection nerveuse caracterisee par de l'incoordination motrice accompagnee d'echolalie et de copralalie. Arch Neurol (Paris) 1885; 9: 19-42, 158-200.
152. Gillman MA, Sandyk R. Clonazepam-induced Tourette syndrome in a subject with hyperexplexia [letter]. Postgrad Med J 1987; 63: 311-2.
153. Goetz CG. Clonidine and clonazepam in Tourette syndrome. [Review]. Adv Neurol 1992; 58: 245-51.
154. Goetz CG, Klawans HL. Gilles de la Tourette on Tourette syndrome. Adv Neurol 1982; 35: 1-16.
155. Goetz CG, Tanner CM, Klawans HL. Fluphenazine and multifocal tic disorders. Arch Neurol 1984; 41: 271-2.
156. Goetz CG, Tanner CM, Wilson RS, Carroll VS, Garron PG, Shannon KM. Clonidine and Gilles de la Tourette's syndrome: double-blind study using objective rating methods. Ann Neurol 1987; 21: 307-10.
157. Goetz CG, Stebbins GT, Thelen JA. Talipexole and adult Gilles de la Tourette's syndrome: double-blind, placebo-controlled clinical trial. Mov Disord 1994; 9: 315-7.
158. Goforth EG. A single case study. Gilles de la Tourette's syndrome. J Nerv Ment Dis 1974; 158: 306-9.
159. Golden GS. Psychologic and neuropsychologic aspects of Tourette's syndrome. Neurol Clin 1984; 21: 91-102.
160. Goldstein JA. Nifedipine treatment of Tourette's syndrome [letter]. J Clin Psychiatry 1984; 45: 360.
161. Gonce M, Barbeau A. Seven cases of Gilles de la Tourette's syndrome: partial relief with clonazepam: a pilot study. Can J Neurol Sci 1977; 4: 279-83.
162. Goodman R. A modified version of the Rutter Parent Questionnaire including extra items on children's strengths: a research note. J Child Psychol Psychiatry 1994; 35: 1483-94.
163. Goodman R. The Strengths and Difficulties Questionnaire: a research note. J Child Psychol Psychiatry 1997; 38: 581-6.
164. Grad LR, Pelcovitz D, Olson M, Matthews M, Grad GJ. Obsessive-compulsive symptomatology in children with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1987; 26: 69-73.
165. Greist J, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, el al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995; 52: 289-95.
166. Grieco MH, Reddy MM, Manvar D, Ahuja KK, Moriarty ML. In-vivo immunomodulation by isoprinosine in patients with the acquired immunodeficiency syndrome and related complexes. Ann Intern Med 1984; 101: 206-7.
167. Gualtieri CT, Keenan PA, Chandler M. Clinical and neuropsychological effects of desipramine in children with attention deficit hyperactivity disorder. J Clin Psychopharmacol 1991; 11: 155-9.
168. Haggstrom JE. Sulpiride in tardive dyskinesia. Curr Ther Res 1980; 27: 164-9.
169. Hallett JJ, Kiessling LS. Neuroimmunology of tics and other childhood hyperkinesias. [Review]. Neurol Clin 1997; 15: 333-44.
170. Hamra BJ, Dunner FH, Larson C. Remission of ties with lithium therapy: case report. J Clin Psychiatry 1983; 44: 73-4.
171. Handley SL, Dursun SM. Serotonin and human tic disorders: implications of rodent tic-like movements including head- and wet-dog shakes. Adv Biosci 1992; 85: 235-53.
172. Hasstedt SJ, Leppert M, Filloux F, van de Wetering BJ, McMahon WM. Intermediate inheritance of Tourette syndrome, assuming assortative mating. Am J Hum Genet 1995; 57: 682-9.
173. Hebebrand J, Klug B, Fimmers R, Seuchter SA, Wettke-Schäfer R, Deget F, et al. Rates for tic disorders and obsessive compulsive symptomatology in families of children and adolescents with Gilles de la Tourette syndrome. J Psychiatr Res 1997; 31: 519-30.
174. Heiser JF, Sramek JJ. More on Tourette syndrome and school phobia [letter]. Am J Psychiatry 1986; 143: 265.
175. Hemming M, Yellowlees PM. Effective treatment of Tourette's syndrome with marijuana. J Psychopharmacol 1993; 7: 389-91.
176. Heutink P, Breedveld GJ, Niermeijer MF, van de Wetering BJ, Oostra BA. Progress in gene localization. In: Kurlan R, editor. Handbook of Tourette's syndrome and related tic and behavioral disorders. New York: Marcel Dekker; 1993. p. 317-35.
177. Hoge SK, Biederman J. A case of Tourette's syndrome with symptoms of attention deficit disorder treated with desipramine. J Clin Psychiatry 1986; 47: 478-9.
178. Holzer JC, Goodman WK, McDougle CJ, Baer L, Boyarsky BK, Leckman JF, et al. Obsessive-compulsive disorder with and without a chronic tic disorder. A comparison of symptoms in 70 patients. Br J Psychiatry 1994; 164: 469-73.
179. Horrigan JP, Barnhill LJ. Guanfacine for treatment of attention-deficit hyperactivity disorder in boys. J Child Adolesc Psychopharmacol 1995; 5: 215-23.
180. Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995; 34: 50-4.
181. Itard JMG. Memoire sur quelques fonctions involontaires des appareils de la locomotion de la prehension et de la voix. Archiv Generale Medicine 1825; 8: 385-407.
182. Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995; 56; 423-9.
183. Jaffe E, Tremeau F, Sharif Z, Reider R. Clozapine in tardive Tourette syndrome. Biol Psychiatry 1995; 38: 196-7.
184. Jagger J, Prusoff BA, Cohen DJ, Kidd KK, Carbonari CM, John K. The epidemiology of Tourette's syndrome: a pilot study. Schizophr Bull 1982; 8: 267-78.
185. Jankovic J. Deprenyl in attention deficit associated with Tourette's syndrome. Arch Neurol 1993; 50: 286-8.
186. Jankovic J. Botulinum toxin in the treatment of dystonic tics. Mov Disord 1994; 9: 347-9.
187. Jankovic J. Tourette syndrome. Phenomenology and classification of tics. [Review]. Neurol Clin 1997; 15: 267-75.
188. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997; 48: 358-62.
189. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. [Review]. N Engl J Med 1991; 324: 1186-94.
190. Jankovic J, Hallett M, editors. Therapy with botulinum toxin. New York: Marcel Dekker; 1994.
191. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988; 38: 391-4.
192. Jankovic J, Rohaidy H. Motor, behavioral and pharmacologic findings in Tourette's syndrome. Can J Neurol Sci 1987; 14 (3 Suppl): 541-6.
193. Jankovic J, Glaze DG, Frost JD Jr. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome. Neurology 1984; 34: 688-92.
194. Jee A. Amantidine in neuroleptic malignant syndrome [letter]. Postgrad Med J 1987; 63: 508-9.
195. Kalian M, Lerner V, Goldman M. Atypical variants of tardive dyskinesia, treated by a combination of clozapine with propranolol and clozapine with tetrabenazine. J Nerv Ment Dis 1993; 181: 649-51.
196. Karagianis JL, Nagpurkar R. A case of Tourette syndrome developing during haloperidol treatment. Can J Psychiatry 1990; 35: 228-32.
197. Katona CLE, Robertson MM. Psychiatry at a glance. Oxford: Blackwell Science: 1995.
198. Kerbeshian J, Burd L. Differential responsiveness to lithium in patients with Tourette disorder. Neurosci Biobehav Rev 1988; 12: 247-50.
199. Kerbeshian J, Burd L. Tourette disorder and bipolar symptomatology in childhood and adolescence. Can J Psychiatry 1989; 34: 230-3.
200. Kerbeshian J, Burd L, Klug MG. Comorbid Tourette's disorder and bipolar disorder: an etiologic perspective. Am J Psychiatry 1995; 152: 1646-51.
201. Kiessling LS, Marcotte AC, Culpepper L. Antineuronal antibodies in movement disorders. Pediatrics 1993; 92: 39-43.
202. Kiessling LS, Marcotte AC, Culpepper L. Antineuronal antibodies: tics and obsessive-compulsive symptoms. J Dev Behav Pediatr 1994; 15: 421-5.
203. Klawans HL, Falk AK, Nausieda PA, Weiner WJ. Gilles de la Tourette syndrome after long-term chlorpromazine therapy. Neurology 1978; 28: 1064-6.
204. Klepel H, Gebelt H, Koch RD, Tzenow H. [Treatment of extrapyramidal hyperkineses in childhood with tiapride]. [German]. Psychiatr Neurol Med Psychol (Leipz) 1988; 40: 516-22.
205. Knell ER, Comings DE. Tourette's syndrome and attention-deficit hyperactivity disorder: evidence for a genetic relationship. J Clin Psychiatry 1993; 54: 331-7.
206. Kompoliti K, Goetz CG. Tourette syndrome. Clinical rating and quantitative assessment of tics. [Review]. Neurol Clin 1997; 15: 239-54.
207. Kumar R, Lang AE. Tourette syndrome. Secondary tic disorders. [Review]. Neurol Clin 1997; 15: 309-31.
208. Kuniyoshi M, Inanaga K, Arikawa K, Maeda Y, Nakamura J, Uchimura N. A case of tardive Tourette-like syndrome. Jpn J Psychiatry Neurol 1992; 46: 67-70.
209. Kurlan R. Tourette syndrome. Treatment of tics. [Review]. Neurol Clin 1997a; 15: 403-9.
210. Kurlan R. Diagnostic criteria for genetic studies of Tourette syndrome [letter]. Arch Neurol 1997b; 54: 517-8.
211. Kurlan R. Acute parkinsonism induced by the combination of a serotonin reuptake inhibitor and a neuroleptic in adults with Tourette's syndrome. Mov Disord 1998; 13: 178-9.
212. Kurlan R. Investigating Tourette syndrome as a neurologic sequela of rheumatic fever. CNS Spectrums 1999; 4: 62-7.
213. Kurlan R, Behr J, Medved L, Shoulson I, Pauls D, Kidd JR, et al. Familial Tourette's syndrome: report of a large pedigree and potential for linkage analysis. Neurology 1986; 36: 772-6.
214. Kurlan R, Behr J, Medved L, Shoulson I, Pauls DL, Kidd KK. Severity of Tourette's syndrome in one large kindred. Implication for determination of disease prevalence rate. Arch Neurol 1987; 44: 268-9.
215. Kurlan R, Kersun J, Ballantine HT Jr, Caine ED. Neurosurgical treatment of severe obsessive-compulsive disorder associated with Tourette's syndrome. Mov Disord 1990; 5: 152-5.
216. Kurlan R, Majumdar L, Deeley C, Mudholkar GS, Plumb S, Como PG. A controlled trial of propoxyphene and naltrexone in patients with Tourette's syndrome. Ann Neurol 1991; 30: 19-23.
217. Kurlan R, Como PG, Deeley C, McDermott M, McDermott MP. A pilot controlled study of fluoxetine for obsessive-compulsive symptoms in children with Tourette's syndrome. Clin Neuropharmacol 1993; 16: 167-72.
218. Kurlan R, Whitmore D, Irvine C, McDermott MP, Como PG. Tourette's syndrome in a special education population: a pilot study involving a single school district. Neurology 1994a; 44: 699-702.
219. Kurlan R, Eapen V, Stern J, McDermott MP, Robertson MM. Bilineal transmission in Tourette's syndrome families. Neurology 1994b; 44: 2236-42.
220. Kurlan R, Daragjati C, Como PG, McDermott MP, Trinidad KS, Roddy S, et al. Non-obscene complex socially inappropriate behavior in Tourette's syndrome. J Neuropsychiatry Clin Neurosci 1996; 8: 311-7.
221. Kushner HI. A cursing brain? The histories of Tourette syndrome. Cambridge (MA): Harvard University Press; 1999.
222. Kushner HI, Luzzatti C, Finger S. A perplexing document in the early history of Gilles de la Tourette syndrome: Melotti's rendition of a 'Lecture by Charcot' (including a complete translation from the Italian with commentary). J History Neurosci 1999; 8: 5-20.
223. Laurino JP, Hallett J, Kiessling LS, Benson M, Pelletier T, Kuhn C. An immunoassay for anti-neuronal antibodies associated with involuntary repetitive movement disorders. Ann Clin Lab Sci 1997; 27: 230-5.
224. Lechin F, van der Dijs B, Gómez F, Acosta E, Arocha L. On the use of clonidine and thioproperazine in a woman with Gilles de la Tourette's disease. Biol Psychiatry 1982; 17: 103-8.
225. Leckman JF, Cohen DJ, Detlor J, Young JG, Harcherik D, Shaywitz BA. Clonidine in the treatment of Tourette syndrome: a review of data. Adv Neurol 1982; 35: 391-401.
226. Leckman JF, Detlor J, Harcherik DF, Ort S, Shaywitz BA, Cohen DJ. Short- and long-term treatment of Tourette's syndrome with clonidine: a clinical perspective. Neurology 1985; 35: 343-51.
227. Leckman JF, Cohen DJ, Price RA, Riddle MA, Minderaa RB, Anderson GM, et al. The pathogenesis of Tourette syndrome: a review of data and hypotheses. In: Shah NS, Donald AG, editors. Movement disorders. New York: Plenum Press; 1986. p. 257-72.
228. Leckman JF, Price RA, Walkup JT, Ort S, Pauls DL, Cohen DJ. Nongenetic factors in Gilles de la Tourette's syndrome [letter]. Arch Gen Psychiatry 1987; 44: 100.
229. Leckman JF, Towbin KE, Ort SI, Cohen DJ. Clinical assessment of tic disorder severity. In: Cohen DJ, Bruun RD, Leckman JF, editors. Tourette's syndrome and tic disorders. New York: Wiley; 1988. p. 55-78.
230. Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989; 28: 566-73.
231. Leckman JF, Dolnansky ES. Hardin MT, Clubb M, Walkup JT, Stevenson J, et al. Perinatal factors in the expression of Tourette's syndrome: an exploratory study. J Am Acad Child Adolesc Psychiatry 1990a; 29: 220-6.
232. Leckman JF, Dolnansky ES, Hardin MT, Clubb M, Walkup JT, Stevenson J, et al. Perinatal factors in the expression of Tourette's syndrome: an exploratory study. J Am Acad Child Adolesc Psychiatry 1990b; 29: 220-6.
233. Leckman JF, Hardin MT, Riddle MA, Stevenson J, Ort SI, Cohen DJ. Clonidine treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1991; 48: 324-8.
234. Leckman JF, Walker DE, Cohen DJ. Premonitory urges in Tourette's syndrome. Am J Psychiatry 1993; 150: 98-102.
235. Leckman JF, Walker DE, Goodman WK, Pauls DL, Cohen DJ. 'Just right' perceptions associated with compulsive behavior in Tourette's syndrome. Am J Psychiatry 1994; 151: 675-80.
236. Leckman JF, Grice DE, Barr LD, de Vries AL, Martin C, Cohen DJ, et al. Tic-related vs. non-tic-related obsessive compulsive disorder. Anxiety 1994-95; 1: 208-15.
237. Leckman JF, Zhang H, Vitale A, Lahnin F, Lynch K, Bondi C, et al. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics 1998; 102: 14-9.
238. Lees AJ, Robertson M, Trimble MR, Murray NM. A clinical study of Gilles de la Tourette syndrome in the United Kingdom. J Neurol Neurosurg Psychiatry 1984; 47: 1-8.
239. Levenson JL. Neuroleptic malignant syndrome. [Review]. Am J Psychiatry 1985; 142: 1137-45.
240. Leysen JE, Janssen PM, Gommeren W, Wynants J, Pauwels PJ, Janssen PA. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 1992; 41: 494-508.
241. Lichter DG, Jackson LA. Predictors of clonidine response in Tourette syndrome: implications and inferences. J Child Neurol 1996; 11: 93-7.
242. Lichter DG, Jackson LA, Schachter M. Clinical evidence of genomic imprinting in Tourette's syndrome. Neurology 1995; 45: 924-8.
243. Linet LS. Tourette syndrome, pimozide, and school phobia: the neuroleptic separation anxiety syndrome. Am J Psychiatry 1985; 142: 613-5.
244. Lipcsey A. [Gilles de la Tourette's disease]. [French]. Sem Hop 1983; 59: 695-6.
245. Lipinski JF Jr, Mallya G, Zimmerman P, Pope HG Jr. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989; 50: 339-42.
246. Lipinski JF, Sallee FR, Jackson C, Sethuraman G. Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide. Mov Disord 1997; 12: 402-7.
247. Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996; 57: 167-73.
248. Lombroso PJ, Mack G, Scahill L, King RA, Leckman JF. Exacerbation of Gilles de la Tourette's syndrome associated with thermal stress: a family study. Neurology 1991; 41: 1984-7.
249. Lombroso PJ, Scahill L, King RA, Lynch KA, Chappell PB, Peterson BS, et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 1995; 34: 1147-52.
250. Lucas AR, Kauffman PE, Morris EM. Gilles de la Tourette's disease. A clinical study of fifteen cases. J Am Acad Child Psychiatry 1967; 6: 700-22.
251. Lucas AR, Beard CM, Rajput AH, Kurland LT. Tourette syndrome in Rochester, Minnesota, 1968-1979. Adv Neurol 1982; 35: 267-9.
252. Ludlow CL, Schulz G, Cohen LG, Naunton RF, Warden M, Hallett M. Pathophysiology and treatment of oral-lingual dyskinesia with botulinum toxin [abstract]. Neurology 1988; 38 Suppl 1: 203.
253. Lutz EG, Feldman J. Alternative drug treatments in Gilles de la Tourette's syndrome [letter]. Am J Psychiatry 1977; 134: 98-9.
254. Mak FL, Chung SY, Lee P, Chen S. Tourette syndrome in the Chinese: a follow-up of 15 cases. Adv Neurol 1982; 35: 281-3.
255. Malatesta VJ. Behavioral case formulation: an experimental assessment study of transient tic disorder. J Psychopathol Behav Assess 1990; 12: 219-32.
256. Manderscheid PZ, Sanberg PR, Norman AB, Fogelson HM, McConville BJ, Moss DE. Nicotine markedly potentiates neuroleptic-induced catalepsy [abstract]. Soc Neurosci Abstr 1988; 14: 1257.
257. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993; 50: 565-76.
258. Mannuzza S, Klein RG, Bessler A, Malloy P, LaPadula M. Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry 1998; 155: 493-8.
259. Mansdorf IJ. Assertiveness training in the treatment of a child's tics. J Behav Ther Exp Psychiatry 1986; 17: 29-32.
260. Mason A, Banerjee S, Eapen V, Zeitlin H, Robertson MM. The prevalence of Tourette syndrome in a mainstream school population. Dev Med Child Neurol 1998; 40: 292-6.
261. McConville BJ, Fogelson MH, Norman AB, Klykylo WM, Manderscheid PZ, Parker KW, et al. Nicotine potentiation of haloperidol in reducing tic frequency in Tourette's disorder. Am J Psychiatry 1991; 148: 793-4.
262. McConville BJ, Sanberg PR, Fogelson MH, King J, Cirino P, Parker KW, et al. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder. Biol Psychiatry 1992; 31: 832-40.
263. McConville BJ, Norman AB, Fogelson MH, Erenberg G. Sequential use of opioid antagonists and agonists in Tourette's syndrome [letter]. Lancet 1994; 343: 601.
264. McDougle CJ, Goodman WK, Leckman JF, Barr LC, Heninger GR, Price LH. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol 1993; 13: 354-8.
265. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 1994; 51: 302-8.
266. McDougle CJ, Goodman WK, Price LH. Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. [Review]. J Clin Psychiatry 1994b; 55 Suppl: 24-31.
267. McDougle CJ, Barr LC, Goodman WK, Pelton GH, Aronson SC, Anand A. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 1995; 152: 1812-4.
268. McKeith IG, Williams A, Nicol AR. Clonidine in Tourette syndrome [letter]. Lancet 1981; 1: 270-1.
269. McKerracher DW, Loughnane T, Watson RA. Self-mutilation in female psychopaths. Br J Psychiatry 1968; 114: 829-32.
270. McMahon WM, Leppert M, Filloux F, van de Wetering BJ, Hasstedt S. Tourette symptoms in 161 related family members. Adv Neurol 1992; 58: 159-65.
271. Mercadante MT, Campos MC, Marques-Dias MJ, Miguel EC, Leckman J. Vocal tics in Sydenham's chorea [letter]. J Am Acad Child Adolesc Psychiatry 1997; 36: 305.
272. Merikangas JR, Reynolds CF 3rd. Blepharospasm: successful treatment with clonazepam. Ann Neurol 1979; 5: 401-2.
273. Merikangas JR, Merikangas KR, Kopp U, Hanin I. Blood choline and response to clonazepam and haloperidol in Tourette's syndrome. Acta Psychiatr Scand 1985; 72: 395-9.
274. Messiha FS. Biochemical pharmacology of Gilles de la Tourette's syndrome. [Review]. Neurosci Biobehav Rev 1988; 12: 295-305.
275. Meuldijk R, Colon EJ. Methadone treatment of Tourette's disorder [letter]. Am J Psychiatry 1992; 149: 139-40.
276. Micheli F, Gatto M, Lekhuniec E, Mangone C, Fernandez Pardal M, Pikielny R, et al. Treatment of Tourette's syndrome with calcium antagonists. Clin Neuropharmacol 1990; 13: 77-83.
277. Michultka DM, Blanchard EB, Rosenblum EL. Stress management and Gilles de la Tourette's syndrome. Biofeedback Self Regul 1989; 14: 115-23.
278. Miguel EC, Baer L, Coffey BJ, Rauch SL, Savage CR, O'Sullivan RL, et al. Phenomenological differences appearing with repetitive behaviours in obsessive-compulsive disorder and Gilles de la Tourette's syndrome. Br J Psychiatry 1997; 170: 140-5.
279. Mikkelsen EJ, Detlor J, Cohen DJ. School avoidance and social phobia triggered by haloperidol in patients with Tourette's disorder. Am J Psychiatry 1981; 138: 1572-6.
280. 2 antagonist ritanserin. Psychopharmacol Bull 1990; 26: 373-6.
281. Miyasaki JM, Lang AE. Treatment of drug-induced movement disorders. In: Kurlan R, editor. Treatment of movement disorders. Philadelphia: J.B. Lippincott; 1995. p. 429-74.
282. Mizrahi EM, Holtzman D, Tharp B. Haloperidol-induced tardive dyskinesia in a child with Gilles de la Tourette's disease. Arch Neurol 1980; 37: 380.
283. Moldofsky H, Tullis C, Lamon R. Multiple tic syndrome (Gilles de la Tourette's syndrome). J Nerv Ment Dis 1974; 159: 282-92.
284. Mondrup K, Dupont E, Braendgaard H. Progabide in the treatment of hyperkinetic extrapyramidal movement disorders. Acta Neurol Scand 1985; 72: 341-3.
285. Montgomery SA. Clomipramine in obsessional neurosis: a placebo controlled trial. Pharm Med 1980; 1: 189-92.
286. Montgomery MA, Clayton PJ, Friedhoff AJ. Psychiatric illness in Tourette syndrome patients and first-degree relatives. Adv Neurol 1982; 35: 335-9.
287. Moss DE, Manderscheid PZ, Montgomery SP, Norman AB, Sandberg PR. Nicotine and cannabinoids as adjuncts to neuroleptics in the treatment of Tourette syndrome and other motor disorders. [Review]. Life Sci 1989; 44: 1521-5.
288. Mueller J, Aminoff MJ. Tourette-like syndrome after long-term neuroleptic drug treatment. Br J Psychiatry 1982; 141: 191-3.
289. Müller N. Exacerbation of tics following antidepressant therapy in a case of Gilles-de-la-Tourette syndrome [letter]. Pharmacopsychiatry 1992; 25: 243-4.
290. Müller N, Voderholzer U, Kurtz G, Straube A. Tourette's syndrome associated with restless legs syndrome and akathisia in a family. Acta Neurol Scand 1994; 89: 429-32.
291. Müller N, Putz A, Kathmann N, Lehle R, Günther W, Straube A. Characteristics of obsessive-compulsive symptoms in Tourette's syndrome, obsessive-compulsive disorder, and Parkinson's disease. Psychiatry Res 1997; 70: 105-14.
292. Muller-Vahl KR, Kolbe H, Dengler R. [Gilles de la Tourette syndrome. Effect of nicotine, alcohol and marihuana on clinical symptoms]. [German]. Nervenarzt 1997; 68: 985-9.
293. Munetz MR, Slawsky RC, Neil JF. Tardive Tourette's syndrome treated with clonidine and mesoridazine. Psychosomatics 1985; 26: 254, 257.
294. Munro A. More on Tourette syndrome and school phobia [letter]. Am J Psychiatry 1986; 143: 265-6.
295. Murphy TK, Goodman WK, Fudge MW, Williams RC Jr, Ayoub EM, Dalal M, et al. B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette's syndrome? Am J Psychiatry 1997; 154: 402-7.
296. Nee LE, Caine ED, Polinsky RJ, Eldridge R, Ebert MH. Gilles de la Tourette syndrome: clinical and family study of 50 cases. Ann Neurol 1980; 7: 41-9.
297. Nee LE, Polinsky RJ, Ebert MH. Tourette syndrome: clinical and family studies. Adv Neurol 1982; 35: 291-5.
298. Neglia JP, Glaze DG, Zion TE. Tics and vocalizations in children treated with carbamazepine. Pediatrics 1984; 73: 841-4.
299. Nomura Y, Segawa M. Tourette syndrome in oriental children: clinical and pathophysiological considerations. Adv Neurol 1982; 35: 277-80
300. Nussbaum D, Rogers R. Screening psychiatric patients for Axis II disorders. Can J Psychiatry 1992; 37: 658-60.
301. O'Connor KP, Gareau D, Blowers GH. Changes of construals of tic-producing situations following cognitive and behavioral therapy. Percept Mot Skills 1993; 77: 776-8.
302. Packer LE. Social and educational resources for patients with Tourette syndrome. [Review]. Neurol Clin 1997; 15: 457-73.
303. Pakkenberg H. The effect of tetrabenazine in some hyperkinetic syndromes. Acta Neurol Scand 1968; 44: 391-3.
304. Palumbo D, Maughan A, Kurlan R. Hypothesis III. Tourette syndrome is only one of several causes of a developmental basal ganglia syndrome. [Review]. Arch Neurol 1997; 54: 475-83.
305. Paolucci S, Buttinelli C, Fiume S, Ciani S, Lenzi GL. Treatment of Gilles de la Tourette syndrome with depot neuroleptics. Acta Neurol (Napoli) 1984; 6: 222-4.
306. Patel PI. Quest for the elusive genetic basis of Tourette syndrome [editorial]. [Review]. Am J Hum Genet 1996; 59: 980-2.
307. Pauls DL. Behavioural disorders: lessons in linkage [news]. Nat Genet 1993; 3: 4-5.
308. Pauls DL, Leckman JF. The inheritance of Gilles de la Tourette's syndrome and associated behaviors. N Engl J Med 1986; 315: 993-7.
309. Pauls DL, Hurst CR, Kruger SD, Leckman JF, Kidd KK, Cohen DJ. Gilles da la Tourette's syndrome and attention deficit disorder with hyperactivity. Evidence against a genetic relationship. Arch Gen Psychiatry 1986a; 43: 1177-9.
310. Pauls DL, Leckman JF, Towbin KE, Zahner GE, Cohen DJ. A possible genetic relationship exists between Tourette's syndrome and obsessive-compulsive disorder. Psychopharmacol Bull 1986b; 22: 730-3.
311. Pauls DL, Towbin KE, Leckman JF, Zahner GE, Cohen DJ. Gilles de la Tourette syndrome and obsessive-compulsive disorder: evidence supporting a genetic relationship. Arch Gen Psychiatry 1986c; 43: 1180-2.
312. Pauls DL, Cohen DJ, Kidd KK, Leckman JF. Tourette syndrome and neuropsychiatric disorders: is there a genetic relationship? Am J Hum Genet 1988; 43: 206-17.
313. Pauls DL, Pakstis AJ, Kurlan R, Kidd KK, Leckman JF, Cohen DJ, et al. Segregation and linkage analyses of Tourette's syndrome and related disorders. J Am Acad Child Adolesc Psychiatry 1990; 29: 195-203.
314. Pauls DL, Raymond CL, Stevenson JM, Leckman JF. A family study of Gilles de la Tourette syndrome. Am J Hum Genet 1991; 48: 154-63.
315. Pauls DL, Leckman JF, Cohen DJ. Familial relationship between Gilles de la Tourette's syndrome, attention deficit disorder, learning disabilities, speech disorders, and stuttering. J Am Acad Child Adolesc Psychiatry 1993; 32: 1044-50.
316. Pauls DL, Leckman JF, Cohen DJ. Evidence against a genetic relationship between Tourette's syndrome and anxiety, depression, panic and phobic disorders. Br J Psychiatry 1994; 164: 215-21.
317. Pauls DL, Alsobrook JP 2nd, Goodman W, Rasmussen S, Leckman JF. A family study of obsessive-compulsive disorder. Am J Psychiatry 1995; 152: 76-84.
318. Perera HV. Two cases of Gilles de la Tourette's syndrome treated with haloperidol. Br J Psychiatry 1975; 127: 324-6.
319. Peterson BS, Leckman JF, Scahill L, Naftolin F, Keefe D, Charest NJ, et al. Steroid hormones and Tourette's syndrome: early experience with antiandrogen therapy. J Clin Psychopharmacol 1994; 14: 131-5.
320. Petter T, Richter MA, Sandor P. Clinical features distinguishing patients with Tourette's syndrome and obsessive-compulsive disorder from patients with obsessive-compulsive disorder without tics. J Clin Psychiatry 1998; 59: 456-9.
321. Pitman RK, Green RC, Jenike MA, Mesulam MM. Clinical comparison of Tourette's disorder and obsessive-compulsive disorder. Am J Psychiatry 1987; 144: 1166-71.
322. Polinsky RJ, Ebert MH, Caine ED, Ludlow C, Bassich CJ. Cholinergic treatment in the Tourette syndrome [letter]. N Engl J Med 1980; 302: 1310.
323. Polites DJ, Kruger D, Stevenson I. Sequential treatments in a case of Gilles de la Tourette's syndrome. Br J Med Psychol 1965; 38: 43-52.
324. Popper CW. Combining methylphenidate and clonidine: pharmacologic questions and news reports about sudden death. J Child Adolesc Psychopharmacol 1995; 5: 157-66.
325. Poungvarin N, Devahastin V, Viriyavejakul A. Treatment of various movement disorders with botulinum A toxin injection: an experience of 900 patients. J Med Assoc Thai 1995; 78: 281-8.
326. Prabhakaran N. A case of Gilles de la Tourette's syndrome with some observations on aetiology and treatment. Br J Psychiatry 1970; 116: 539-41.
327. Primeau F, Fontaine R. Obsessive disorder with self-mutilation: a sub-group responsive to pharmacotherapy. Can J Psychiatry 1987; 32: 699-701.
328. Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry 1984; 47: 844-7.
329. Rauch SL, Baer L, Cosgrove GR, Jenike MA. Neurosurgical treatment of Tourette's syndrome: a critical review. [Review]. Compr Psychiatry 1995; 36: 141-56.
330. Realmuto GM, Main B. Coincidence of Tourette's disorder and infantile autism. J. Autism Dev Disord 1982; 12: 367-72.
331. Reccoppa L, Welch WA, Ware MR. Acute dystonia and fluoxetine [letter]. J Clin Psychiatry 1990; 51: 487.
332. Regeur L, Pakkenberg B, Fog R, Pakkenberg H. Clinical features and long-term treatment with pimozide in 65 patients with Gilles de la Tourette's syndrome. J Neurol Neurosurg Psychiatry 1986; 49: 791-5.
333. Reveley MA, Bird R, Stirton RF, Dursun SM. Microstructural analysis of the symptoms of Tourette's syndrome and the effects of a trial use of transdermal nicotine patch [abstract]. J Psychopharmacol 1994; 8 Suppl: A30.
334. Reynolds JEF, editor. Martindale: the extra pharmacopoeia. 31st ed. London: Pharmaceutical Press; 1996.
335. Rickards EH. Nicotine gum in Tourette's disorder [letter]. Am J Psychiatry 1992; 149: 417; discussion 418.
336. Rickards H, Hartley N, Robertson MM. Seignot's paper on the treatment of Tourette's syndrome with haloperidol. Hist Psychiatry 1997; viii: 433-6.
337. Riddle MA, Hardin MT, Towbin KE, Leckman JF, Cohen DJ. Tardive dyskinesia following haloperidol treatment in Tourette's syndrome [letter]. Arch Gen Psychiatry 1987; 44: 98-9.
338. Riddle MA, Leckman JF, Hardin MT, Anderson GM, Cohen DJ. Fluoxetine treatment of obsessions and compulsions in patients with Tourette's syndrome [letter]. Am J Psychiatry 1988; 145: 1173-4.
339. Riddle MA, Hardin MT, King R, Scahill L, Woolston JL. Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1990; 29: 45-8.
340. Riddle MA, Nelson JC, Kleinman CS, Rasmusson A, Leckman JF, King RA, et al. Sudden death in children receiving norpramin: a review of three reported cases and commentary. J Am Acad Child Adolesc Psychiatry 1991; 30: 104-8.
341. Riedel M, Straube A, Schwarz MJ, Wilske B, Müller N. Lyme disease presenting as Tourette's syndrome [letter]. Lancet 1998; 351: 418-9.
342. Robertson MM. The Gilles de la Tourette syndrome: the current status. [Review]. Br J Psychiatry 1989; 154: 147-69.
343. Robertson MM. Annotation: Gilles de la Tourette syndrome - an update. [Review]. J Child Psychol Psychiatry 1994; 35: 597-611.
344. Robertson MM. The relationship between Gilles de la Tourette's syndrome and obsessive compulsive disorder. [Review]. J Serotonin Res 1995; 1 Suppl 1: 49-62.
345. Robertson MM. Structural neuroimaging in Gilles de la Tourette syndrome. In: Garreau B, editor. Neuroimaging in child neuropsychiatrie disorders. Berlin: Springer-Verlag; 1998. p. 127-32.
346. Robertson MM, Eapen V. Pharmacologic controversy of CNS stimulants in Gilles de la Tourette's syndrome. [Review]. Clin Neuropharmacol 1992; 15: 408-25.
347. Robertson MM, Eapen V. The National Hospital Interview Schedule for the assessment of Gilles de la Tourette syndrome. Int J Meth Psychiatr Res 1996; 6: 203-26.
348. Robertson MM, Gourdie A. Familial Tourette's syndrome in a large British pedigree. Associated psychopathology, severity, and potential for linkage analysis. Br J Psychiatry 1990; 156: 515-21.
349. Robertson MM, Reinstein DZ. Convulsive tic disorder. Georges Gilles de la Tourette, Guinon and Grasset on the phenomenology and psychopathology of the Gilles de la Tourette syndrome. Behav Neurol 1991; 4: 29-56.
350. Robertson MM, Stern JS. The Gilles de la Tourette syndrome. [Review]. Crit Rev Neurobiol 1997; 11: 1-19.
351. Robertson MM, Stern JS. Tic disorders: new developments in Tourette syndrome and related disorders. [Review]. Curr Opin Neurol 1998; 11: 373-80.
352. Robertson MM, Yakeley JW. Obsessive-compulsive disorder and self-injurious behaviour. In: Kurlan R, editor. Handbook of Tourette's syndrome and related tic and behavioral disorders. New York: Marcel Dekker; 1993. p. 45-87.
353. Robertson MM, Trimble MR, Lees AJ. The psychopathology of the Gilles de la Tourette syndrome: a phenomenological analysis. Br J Psychiatry 1988; 152: 383-90.
354. Robertson MM, Trimble MR, Lees AJ. Self-injurious behaviour and the Gilles de la Tourette syndrome: a clinical study and review of the literature. Psychol Med 1989; 19: 611-25.
355. Robertson M, Doran M, Trimble M, Lees AJ. The treatment of Gilles de la Tourette syndrome by limbic leucotomy. J Neurol Neurosurg Psychiatry 1990a; 53: 691-4.
356. Robertson MM, Schnieden V, Lees AJ. Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropharmacol 1990b; 13: 229-35.
357. Robertson MM, Channon S, Baker J, Flynn D. The psychopathology of Gilles de la Tourette Syndrome: a controlled study. Br J Psychiatry 1993; 162: 114-7.
358. Robertson MM, Scull DA, Eapen V, Trimble MR. Risperidone in the treatment of Tourette syndrome: a retrospective case note study. J Psychopharmacol 1996; 10: 317-20.
359. Robertson MM, Banerjee S, Hiley PJ, Tannock C. Personality disorder and psychopathology in Tourette's syndrome: a controlled study. Br J Psychiatry 1997; 171: 283-6.
360. Ross MS, Moldofsky H. Comparison of pimozide with haloperidol in Gilles de la Tourette's syndrome [letter]. Lancet 1977; 1: 103.
361. Ross MS, Moldofsky H. A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome. Am J Psychiatry 1978; 135: 585-7.
362. Rowan AB, Malone RP. Tics with risperidone withdrawal [letter]. J Am Acad Child Adolesc Psychiatry 1997; 36: 162-3.
363. Sallee FR, Sethuraman G, Rock CM. Effects of pimozide on cognition in children with Tourette syndrome: interaction with comorbid attention deficit hyperactivity disorder. Acta Psychiatr Scand 1994; 90: 4-9.
364. Sallee FR, Dougherty D, Sethuraman G, Vrindavanam N. Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette's syndrome. Biol Psychiatry 1996; 40: 1044-50.
365. Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry 1997; 154: 1057-62.
366. Salmon G, James A, Smith DM. Bullying in schools: self reported anxiety, depression, and self esteem in secondary school children. BMJ 1998; 317: 924-5.
367. Sanberg PR, Fogelson HM, Manderscheid PZ, Parker KW, Norman AB, McConville BJ. Nicotine gum and haloperidol in Tourette's syndrome [letter]. Lancet 1988; 1: 592.
368. Sanberg PR, McConville BJ, Fogelson HM, Manderscheid PZ, Parker KW, Blythe MM, et al. Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome. Biomed Pharmacother 1989; 43: 19-23.
369. Sanberg PR, Shytle RD, Silver AA. Treatment of Tourette's syndrome with mecamylamine [letter]. Lancet 1998; 352: 705-6.
370. Sandor P, Musisi S, Moldofsky H, Lang A. Tourette syndrome: a follow-up study. J Clin Psychopharmacol 1990; 10: 197-9.
371. Sandor P, Singal S, Angus C. Remoxipride vs. haloperidol treatment of Tourette's syndrome [abstract]. Mov Disord 1996; 11 Suppl 1: 248.
372. Sandyk R. Naloxone ameliorates autoaggressive behavior in Tourette's syndrome [abstract]. Neurology 1986a; 36 Suppl 1: 275.
373. Sandyk R. Naloxone withdrawal exacerbates Tourette syndrome [letter]. J Clin Psychopharmacol 1986b; 6: 58-9.
374. Sandyk R, Awerbuch G. Marijuana and Tourette's syndrome [letter]. J Clin Psychopharmacol 1988; 8: 444-5.
375. Sandyk R, Iacono RP, Crinnian C, Bamford CR, Consroe PF. Effects of naltrexone in Tourette's syndrome [abstract]. Ann Neurol 1986a; 20: 437.
376. Sandyk R, Iacono RP, Allender J. Naloxone ameliorates compulsive touching behavior and tics in Tourette's syndrome [abstract]. Ann Neurol 1986b; 20: 437.
377. Sandyk R, Bamford CR, Laguna J. Clomiphene citrate in Tourette's syndrome [letter]. Postgrad Med J 1987; 63: 510-1.
378. Scahill L, Riddle MA, King RA, Hardin MT, Rasmusson A, Makuch RW, et al. Fluoxetine has no marked effect on tic symptoms in patients with Tourette's syndrome: a double-blind placebo-controlled study. J Child Adolesc Psychopharmacol 1997; 7: 75-85.
379. Schmider J, Hoff P. Clozapine in Tourette's syndrome [letter]. J Clin Psychopharmacol 1998; 18: 88-9.
380. Schwartz M, Moguillansky L, Lanyi G, Sharf B. Sulpiride in tardive dyskinesia. J Neurol Neurosurg Psychiatry 1990; 53: 800-2.
381. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. [Review]. Trans Am Ophthalmol Soc 1981; 79: 734-70.
382. Scott AB, Magoon EH, McNeer KW, Stager DR. Botulinum treatment of childhood strabismus. Ophthalmology 1990; 97: 1434-8.
383. Scott BL, Jankovic J, Donovan DT. Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette's syndrome. Mov Disord 1996; 11: 431-3.
384. Seeman MV, Patel J, Pyke J. Tardive dyskinesia with Tourette-like syndrome. J Clin Psychiatry 1981; 42: 357-8.
385. Seignot MJN. [A case of tic of Gilles de la Tourette cured by R 1625]. [French]. Ann Med Psychol 1961; 119: 578-9.
386. Shale H, Tanner C. Pharmacological options for the management of dyskinesias. [Review]. Drugs 1996; 52: 849-60.
387. Shapiro AK, Shapiro E. Treatment of Gilles de la Tourette's syndrome with haloperidol. Br J Psychiatry 1968; 114: 345-50.
388. Shapiro AK, Shapiro E. Clinical efficacy of haloperidol, pimozide, penfluridol, and clonidine in the treatment of Tourette syndrome. Adv Neurol 1982; 35: 383-6.
389. Shapiro AK, Shapiro E. Controlled study of pimozide vs. placebo in Tourette's syndrome. J Am Acad Child Psychiatry 1984; 23: 161-73.
390. Shapiro AK, Shapiro E, Wayne HL. The symptomatology and diagnosis of Gilles de la Tourette's syndrome. J Am Acad Child Psychiatry 1973a; 12: 702-23.
391. Shapiro AK, Shapiro E, Wayne HL, Clarkin J, Bruun RD. Tourette's syndrome: summary of data on 34 patients. [Review]. Psychosom Med 1973b; 35: 419-35.
392. Shapiro AK, Shapiro E, Wayne H. Treatment of Tourette's syndrome with haloperidol: review of 34 cases. Arch Gen Psychiatry 1973c; 28: 92-7.
393. Shapiro AK, Shapiro E, Eisenkraft GJ. Treatment of Gilles de la Tourette's syndrome with clonidine and neuroleptics. Arch Gen Psychiatry 1983a; 40: 1235-40.
394. Shapiro AK, Shapiro E, Eisenkraft GJ. Treatment of Tourette disorder with penfluridol. Compr Psychiatry 1983b: 24: 327-31.
395. Shapiro AK, Shapiro ES, Young JG, Feinberg TE. Gilles de la Tourette syndrome. 2nd ed. New York: Raven Press; 1988.
396. Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandeli J, Nordlie J, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1989; 46: 722-30.
397. Shapleske J, McKay AP, McKenna PJ. Successful treatment of tardive dystonia with clozapine and clonazepam. Br J Psychiatry 1996; 168: 516-8.
398. Shihabuddin L, Rapport D. Sertraline and extrapyramidal side effects [letter]. Am J Psychiatry 1994; 151: 288.
399. Shulman LM, Singer C, Weiner WJ. Risperidone in Gilles de la Tourette syndrome. Neurology 1995; 45: 1419.
400. Silva R, Magee H, Friedhoff A. Persistent tardive dyskinesia and other neuroleptic-related dyskinesias in Tourette's disorder. J Child Adolesc Psychopharmacol 1993; 3: 137-44.
401. Silva RR, Munoz DM, Barickman J, Friedhoff AJ. Environmental factors and related fluctuation of symptoms in children and adolescents with Tourette's disorder. J Child Psychol Psychiatry 1995; 36: 305-12.
402. Silver AA, Sanberg PR. Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome [letter]. Lancet 1993; 342: 182.
403. Silver AA, Shytle RD, Philipp MK, Sanberg PR. Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1996; 35: 1631-6.
404. Silvestri R, Raffaele M, De Domenico P, Tisano A, Lagana A, Di Perri R. Serotoninergic agents in the treatment of Gilles de la Tourette's syndrome. Acta Neurol (Napoli) 1994; 16: 58-63.
405. Singer HS. Neurobiology of Tourette syndrome. [Review]. Neurol Clin 1997; 15: 357-79.
406. Singer HS, Rosenberg LA. Development of behavioral and emotional problems in Tourette syndrome. Pediatr Neurol 1989; 5: 41-4.
407. Singer HS, Rabins P, Tune LE, Coyle JT. Serum haloperidol levels in Gilles de la Tourette syndrome. Biol Psychiatry 1981; 16: 79-84.
408. Singer HS, Butler IJ, Tune LE, Seifert WE Jr, Coyle JT. Dopaminergic dysfunction in Tourette syndrome. Ann Neurol 1982; 12: 361-6.
409. Singer HS, Gammon K, Quaskey S. Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr Neurosci 1986; 12: 71-4.
410. Singer HS, Brown J, Quaskey S, Rosenberg LA, Mellits ED, Denckla MB. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 1995a; 95: 74-81.
411. Singer HS, Schuerholz LJ, Denckla MB. Learning difficulties in children with Tourette syndrome. [Review]. J Child Neurol 1995b; 10 Suppl 1: S58-61.
412. Singh SK, Jankovic J. Tardive dystonia in patients with Tourette's syndrome. Mov Disord 1988; 3: 274-80.
413. Smirnov A. Use of metoclopramide (cerucal) in Tourette syndrome. Zh Nevropatol Psikhiatr 1989; 89: 105-8.
414. Spencer T, Biederman J, Wilens T, Steingard R, Geist D. Nortriptyline in the treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1993; 32: 205-10.
415. Spencer T, Biederman J, Harding M, Wilens T, Faraone S. The relationship between tic disorders and Tourette's syndrome revisited. J Am Acad Child Adolesc Psychiatry 1995; 34: 1133-9.
416. Spencer T, Biederman J, Harding M, O'Donnell D, Wilens T, Faraone S, et al. Disentangling the overlap between Tourette's disorder and ADHD. J Child Psychol Psychiatry 1998; 39: 1037-44.
417. Spencer T, Biederman J, Coffey B, Geller D, Wilens T, Faraone S. The 4-year course of tic disorders in boys with attention-deficit/ hyperactivity disorder. Arch Gen Psychiat 1999; 56: 842-7.
418. Spitzer RL, Williams JBW, Gibbon M. Structured clinical interview for DSM-III-R - patient version. Research Department, New York State Psychiatric Institute, New York: Biometrics; 1987.
419. Stahl SM. Tardive Tourette syndrome in an autistic patient after long-term neuroleptic administration. Am J Psychiatry 1980; 137: 1267-9.
420. Stahl SM, Berger PA. Physostigmine in Gilles de la Tourette's syndrome [letter]. N Engl J Med 1980; 302: 298.
421. Stahl SM, Berger PA. Physostigmine in Tourette syndrome: evidence for cholinergic underactivity. Am J Psychiatry 1981; 138: 240-2.
422. Staley D, Wand R, Shady G. Tourette disorder: a cross-cultural review. [Review]. Compr Psychiatry 1997; 38: 6-16.
423. Stamenkovic M, Aschauer H, Kasper S. Risperidone for Tourette's syndrome [letter]. Lancet 1994; 344: 1577-8.
424. Stanciu E, Csiky K, Csiky C. [On a case of tics (Gilles de la Tourette's disease) treated with haloperidol]. [Romanian]. Neurol Psihiatr Neurochir 1972; 17: 43-8.
425. Stefl ME. Mental health needs associated with Tourette syndrome. Am J Public Health 1984; 74: 1310-3.
426. Stein DJ, Bouwer C, Hawkridge S, Emsley RA. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997; 58: 119-22.
427. Stern JS, Robertson MM. Tics associated with autistic and pervasive developmental disorders. [Review]. Neurol Clin 1997; 15: 345-55.
428. Stevens H. The syndrome of Gilles de la Tourette and its treatment: report of a case. Med Ann DC 1964; 33: 277-9.
429. Stevens JR, Blachly PH. Successful treatment of the maladie des tics. Gilles de la Tourette's syndrome. Am J Dis Child 1966; 112: 541-5.
430. Stinnett JL, Hollender MH. Compulsive self-mutilation. J Nerv Ment Dis 1970; 150: 371-5.
431. Stone L, Jankovic J. The coexistence of tics and dystonia. Arch Neurol 1991; 48: 862-5.
432. Surwillo WW, Shafii M, Barrett CL. Gilles de la Tourette syndrome: a 20-month study of the effects of stressful life events and haloperidol on symptom frequency. J Nerv Ment Dis 1978; 166: 812-6.
433. Swedo SE, Rapoport JL, Cheslow DL, Leonard HL, Ayoub EM, Hosier DM, et al. High prevalence of obsessive-compulsive symptoms in patients with Sydenham's chorea. Am J Psychiatry 1989; 146: 246-9.
434. Swedo SE, Leonard HL, Schapiro MB, Casey BJ, Mannheim GB, Lenane MC, et al. Sydenham's chorea: physical and psychological symptoms of St Vitus dance. Pediatrics 1993; 91: 706-13.
435. Swedo SE, Leonard HL, Kiessling LS. Speculations on antineuronal antibody-mediated neuropsychiatric disorders of childhood. Pediatrics 1994; 93: 323-6.
436. Swedo SE, Leonard HL, Mittleman BB, Allen AJ, Rapoport JL, Dow SP, et al. Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Am J Psychiatry 1997; 154: 110-2.
437. Swedo SE, Leonard HL, Garvey M, Mittleman B, Allen AJ, Perlmutter S, et al. Pediatric autoimmune neuropsychiatrie disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998; 155: 264-71.
438. Sweet RD, Bruun R, Shapiro E, Shapiro AK. Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine. Arch Gen Psychiatry 1974; 31: 857-61.
439. Tanner CM, Goldman SM. Epidemiology of Tourette syndrome. [Review]. Neurol Clin 1997; 15: 395-402.
440. Tate JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine [letter]. Am J Psychiatry 1989; 146: 399-400.
441. Taylor E, Sergeant J, Doepfner M, Gunning B, Overmeyer S, Mobius HJ, et al. Clinical guidelines for hyperkinetic disorder. Eur Child Adolesc Psychiatry 1998; 7: 184-200.
442. Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 1990; 147: 445-51.
443. Thibert AL, Day HI, Sandor P. Self-concept and self-consciousness in adults with Tourette syndrome. Can J Psychiatry 1995; 40: 35-9.
444. Thoren P, Asberg M, Cronholm B, Jornestedt L, Traskman L. Clompiramine treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1980; 37: 1281-5.
445. Tourette Syndrome Association International Consortium for Genetics. A complete genome screen in sib-pairs affected with the Gilles de la Tourette syndrome. Am J Hum Genetics 1999; 65: 1428-36.
446. Towbin KE, Riddle MA. Attention deficit hyperactivity disorder. In: Kurlan R, editor. Handbook of Tourette's syndrome and related tic and behavioral disorders. New York: Marcel Dekker; 1993. p. 89-109.
447. Traverse L. Prevalence of Tourette syndrome in a mainstream school population. Dev Med Child Neurology 1998; 40: 847.
448. Trillet M, Moreau T, Dalery J, de Villard R, Aimard G. [Treatment of Gilles de la Tourette's disease with amisulpride] [letter]. Presse Med 1990; 19: 175.
449. Trimble MR, Whurr R, Brookes G, Robertson, MM. Vocal tics in Gilles de la Tourette syndrome treated with botulinum toxin injections. Mov Disord 1998; 13: 617-9.
450. Uhr SB, Pruitt B, Berger PA, Stahl SM. Improvement of symptoms in Tourette syndrome by piquindone, a novel dopamine-2 receptor antagonist. Int Clin Psychopharmacol 1986; 1: 216-20.
451. van der Linden C, Bruggeman R, van Woerkom TCA. Serotonin-dopamine antagonist and Gilles de la Tourette's syndrome; an open pilot dose-titration study with risperidone [letter]. Mov Disord 1994; 9: 687-8.
452. van de Wetering BJ, Cohen AP, Minderaa RB, Roos RA, van Woerkom TC. [Gilles de la Tourette syndrome]. [Dutch]. Ned Tijdschr Geneeskd 1988; 132: 21-5.
453. Van Woert MJ, Jutkowitz R, Rosenbaum D, Bowers MB Jr. Gilles de la Tourette's syndrome: biochemical approaches. Res Publ Assoc Res Nerv Ment Dis 1976; 55: 459-65.
454. Varma SK, Messiha FS. Endocrine aspects of lithium therapy in Tourette's syndrome. Brain Res Bull 1983; 11: 209-11.
455. Walkup JT, LaBuda MC, Singer HS, Brown J, Riddle MA, Hurko O. Family study and segregation analysis of Tourette syndrome: evidence for a mixed model of inheritance. Am J Hum Genet 1996; 59: 684-93.
456. Walsh TL, Lavenstein B, Licamele WL, Bronheim S, O'Leary J. Calcium antagonists in the treatment of Tourette's disorder. Am J Psychiatry 1986; 143: 1467-8.
457. Weiss G, Hechtman L, Milroy T, Perlman T. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry 1985; 24: 211-20.
458. Weiss D, Aizenberg D, Hermesh H, Zemishlany Z, Munitz H, Radwan M, et al. Cyproheptadine treatment in neuroleptic-induced akathisia. Br J Psychiatry 1995; 167: 483-6.
459. Witzum E, Bar-On R, Dolberg OT, Kotler M. Traumatic war experiences affect outcome in a case of Tourette's syndrome. Psychother Psychosom 1996; 65: 106-8.
460. Wodrich DL, Benjamin E, Lachar D. Tourette's syndrome and psychopathology in a child psychiatry setting. J Am Acad Child Adolesc Psychiatry 1997; 36: 1618-24.
461. World Health Organization. International statistical classification of diseases and related health problems: ICD-10. 10th revision. Geneva: World Health Organization; 1992.
462. Wright S, Peet M. Gilles de la Tourette's syndrome. Amelioration following acute akinesia during lorazepam withdrawal. Br J Psychiatry 1989; 154: 257-9.
463. Wu L, Li H, Kang L. 156 cases of Gilles de la Tourette's syndrome treated by acupuncture. J Tradit Chin Med 1996; 16: 211-3.
464. Yassa R, Ananth J. Lithium carbonate in the treatment of movement disorders. A critical review. [Review]. Int Pharmacopsychiatry 1980; 15: 301-8.
465. Yvonneau M, Bezard P. [Apropos of a case of Gilles de la Tourette's disease blocked by sulpiride. Psycho-biological study]. [French]. Encephale 1970; 59: 439-59.
466. Zausmer DM. Treatment of tics in childhood. Arch Dis Child 1954; 29: 537-42.
467. Zohar AH, Pauls DL, Ratzoni G, Apter A, Dycian A, Binder M, et al. Obsessive-compulsive disorder with and without tics in an epidemiological sample of adolescents. Am J Psychiatry 1997; 154: 274-6.
468. Zubenko GS, Cohen BM, Lipinski JF Jr, Jonas JM. Use of clonidine in treating neuroleptic-induced akathisia. Psychiatry Res 1984; 13: 253-9.